Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 85

1.

Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies.

Hernandez C, Arasanz H, Chocarro L, Bocanegra A, Zuazo M, Fernandez-Hinojal G, Blanco E, Vera R, Escors D, Kochan G.

Int J Mol Sci. 2020 Mar 31;21(7). pii: E2411. doi: 10.3390/ijms21072411. Review.

2.

Early Detection of Hyperprogressive Disease in Non-Small Cell Lung Cancer by Monitoring of Systemic T Cell Dynamics.

Arasanz H, Zuazo M, Bocanegra A, Gato M, Martínez-Aguillo M, Morilla I, Fernández G, Hernández B, López P, Alberdi N, Hernández C, Chocarro L, Teijeira L, Vera R, Kochan G, Escors D.

Cancers (Basel). 2020 Feb 4;12(2). pii: E344. doi: 10.3390/cancers12020344.

3.

Short-Term Local Expression of a PD-L1 Blocking Antibody from a Self-Replicating RNA Vector Induces Potent Antitumor Responses.

Ballesteros-Briones MC, Martisova E, Casales E, Silva-Pilipich N, Buñuales M, Galindo J, Mancheño U, Gorraiz M, Lasarte JJ, Kochan G, Escors D, Sanchez-Paulete AR, Melero I, Prieto J, Hernandez-Alcoceba R, Hervas-Stubbs S, Smerdou C.

Mol Ther. 2019 Nov 6;27(11):1892-1905. doi: 10.1016/j.ymthe.2019.09.016. Epub 2019 Sep 16.

PMID:
31563534
4.

Functional systemic CD4 immunity is required for clinical responses to PD-L1/PD-1 blockade therapy.

Zuazo M, Arasanz H, Fernández-Hinojal G, García-Granda MJ, Gato M, Bocanegra A, Martínez M, Hernández B, Teijeira L, Morilla I, Lecumberri MJ, Fernández de Lascoiti A, Vera R, Kochan G, Escors D.

EMBO Mol Med. 2019 Jul;11(7):e10293. doi: 10.15252/emmm.201910293. Epub 2019 Jun 6.

5.

Perforin and Granzyme B Expressed by Murine Myeloid-Derived Suppressor Cells: A Study on Their Role in Outgrowth of Cancer Cells.

Dufait I, Pardo J, Escors D, De Vlaeminck Y, Jiang H, Keyaerts M, De Ridder M, Breckpot K.

Cancers (Basel). 2019 Jun 11;11(6). pii: E808. doi: 10.3390/cancers11060808.

6.

PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer.

Bocanegra A, Fernandez-Hinojal G, Zuazo-Ibarra M, Arasanz H, Garcia-Granda MJ, Hernandez C, Ibañez M, Hernandez-Marin B, Martinez-Aguillo M, Lecumberri MJ, Fernandez de Lascoiti A, Teijeira L, Morilla I, Vera R, Escors D, Kochan G.

Int J Mol Sci. 2019 Apr 2;20(7). pii: E1631. doi: 10.3390/ijms20071631.

7.

Radiopotentiation of enzalutamide over human prostate cancer cells as assessed by real-time cell monitoring.

Barrado M, Blanco-Luquin I, Navarrete PA, Visus I, Guerrero-Setas D, Escors D, Kochan G, Arias F.

Rep Pract Oncol Radiother. 2019 Mar-Apr;24(2):221-226. doi: 10.1016/j.rpor.2019.02.002. Epub 2019 Feb 22.

8.

Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies.

Arasanz H, Zuazo M, Vera R, Kochan G, Escors D.

Lung Cancer Manag. 2018 Dec 20;7(3):LMT07. doi: 10.2217/lmt-2018-0014. eCollection 2018 Nov. No abstract available.

9.

Cancer Immunotherapy of TLR4 Agonist-Antigen Constructs Enhanced with Pathogen-Mimicking Magnetite Nanoparticles and Checkpoint Blockade of PD-L1.

Traini G, Ruiz-de-Angulo A, Blanco-Canosa JB, Zamacola Bascarán K, Molinaro A, Silipo A, Escors D, Mareque-Rivas JC.

Small. 2019 Jan;15(4):e1803993. doi: 10.1002/smll.201803993. Epub 2018 Dec 20.

PMID:
30569516
10.

The intracellular signalosome of PD-L1 in cancer cells.

Escors D, Gato-Cañas M, Zuazo M, Arasanz H, García-Granda MJ, Vera R, Kochan G.

Signal Transduct Target Ther. 2018 Sep 28;3:26. doi: 10.1038/s41392-018-0022-9. eCollection 2018. Review.

11.

Molecular Recalibration of PD-1+ Antigen-Specific T Cells from Blood and Liver.

Otano I, Escors D, Schurich A, Singh H, Robertson F, Davidson BR, Fusai G, Vargas FA, Tan ZMD, Aw JYJ, Hansi N, Kennedy PTF, Xue SA, Stauss HJ, Bertoletti A, Pavesi A, Maini MK.

Mol Ther. 2018 Nov 7;26(11):2553-2566. doi: 10.1016/j.ymthe.2018.08.013. Epub 2018 Aug 16.

12.

Effective cancer immunotherapy in mice by polyIC-imiquimod complexes and engineered magnetic nanoparticles.

Bocanegra Gondan AI, Ruiz-de-Angulo A, Zabaleta A, Gómez Blanco N, Cobaleda-Siles BM, García-Granda MJ, Padro D, Llop J, Arnaiz B, Gato M, Escors D, Mareque-Rivas JC.

Biomaterials. 2018 Jul;170:95-115. doi: 10.1016/j.biomaterials.2018.04.003. Epub 2018 Apr 3.

PMID:
29656235
13.

Characterization of Macrophage Endogenous S-Nitrosoproteome Using a Cysteine-Specific Phosphonate Adaptable Tag in Combination with TiO2 Chromatography.

Ibáñez-Vea M, Huang H, Martínez de Morentin X, Pérez E, Gato M, Zuazo M, Arasanz H, Fernández-Irigoyen J, Santamaría E, Fernandez-Hinojal G, Larsen MR, Escors D, Kochan G.

J Proteome Res. 2018 Mar 2;17(3):1172-1182. doi: 10.1021/acs.jproteome.7b00812. Epub 2018 Jan 25.

PMID:
29338241
14.

Molecular mechanisms of programmed cell death-1 dependent T cell suppression: relevance for immunotherapy.

Zuazo M, Gato-Cañas M, Llorente N, Ibañez-Vea M, Arasanz H, Kochan G, Escors D.

Ann Transl Med. 2017 Oct;5(19):385. doi: 10.21037/atm.2017.06.11. Review.

15.

Myeloid-Derived Suppressor Cells in the Tumor Microenvironment: Current Knowledge and Future Perspectives.

Ibáñez-Vea M, Zuazo M, Gato M, Arasanz H, Fernández-Hinojal G, Escors D, Kochan G.

Arch Immunol Ther Exp (Warsz). 2018 Apr;66(2):113-123. doi: 10.1007/s00005-017-0492-4. Epub 2017 Oct 14. Review.

PMID:
29032490
16.

PD1 signal transduction pathways in T cells.

Arasanz H, Gato-Cañas M, Zuazo M, Ibañez-Vea M, Breckpot K, Kochan G, Escors D.

Oncotarget. 2017 Apr 19;8(31):51936-51945. doi: 10.18632/oncotarget.17232. eCollection 2017 Aug 1. Review.

17.

PDL1 Signals through Conserved Sequence Motifs to Overcome Interferon-Mediated Cytotoxicity.

Gato-Cañas M, Zuazo M, Arasanz H, Ibañez-Vea M, Lorenzo L, Fernandez-Hinojal G, Vera R, Smerdou C, Martisova E, Arozarena I, Wellbrock C, Llopiz D, Ruiz M, Sarobe P, Breckpot K, Kochan G, Escors D.

Cell Rep. 2017 Aug 22;20(8):1818-1829. doi: 10.1016/j.celrep.2017.07.075.

18.

Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery.

Goyvaerts C, De Vlaeminck Y, Escors D, Lienenklaus S, Keyaerts M, Raes G, Breckpot K.

Gene Ther. 2017 Jun;24(6):370-375. doi: 10.1038/gt.2017.30. Epub 2017 May 25.

PMID:
28540936
19.

Non-invasive assessment of murine PD-L1 levels in syngeneic tumor models by nuclear imaging with nanobody tracers.

Broos K, Keyaerts M, Lecocq Q, Renmans D, Nguyen T, Escors D, Liston A, Raes G, Breckpot K, Devoogdt N.

Oncotarget. 2017 Jun 27;8(26):41932-41946. doi: 10.18632/oncotarget.16708.

20.

Immunotherapy in malignant melanoma: recent approaches and new perspectives.

Arasanz H, Lacalle A, Lecumberri MJ, de Lascoiti ÁF, Blanco-Luquin I, GatoCañas M, Pérez-Ricarte L, Zuazo M, Kochan G, Escors D.

Melanoma Manag. 2017 Mar;4(1):39-48. doi: 10.2217/mmt-2016-0019. Epub 2017 Mar 1. Review.

21.

CHL1 hypermethylation as a potential biomarker of poor prognosis in breast cancer.

Martín-Sánchez E, Mendaza S, Ulazia-Garmendia A, Monreal-Santesteban I, Blanco-Luquin I, Córdoba A, Vicente-García F, Pérez-Janices N, Escors D, Megías D, López-Serra P, Esteller M, Illarramendi JJ, Guerrero-Setas D.

Oncotarget. 2017 Feb 28;8(9):15789-15801. doi: 10.18632/oncotarget.15004.

22.

Dendritic Cells Cross-Present Immunogenic Lentivector-Encoded Antigen from Transduced Cells to Prime Functional T Cell Immunity.

Hotblack A, Seshadri S, Zhang L, Hamrang-Yousefi S, Chakraverty R, Escors D, Bennett CL.

Mol Ther. 2017 Feb 1;25(2):504-511. doi: 10.1016/j.ymthe.2016.11.001.

23.

A sestrin-dependent Erk-Jnk-p38 MAPK activation complex inhibits immunity during aging.

Lanna A, Gomes DC, Muller-Durovic B, McDonnell T, Escors D, Gilroy DW, Lee JH, Karin M, Akbar AN.

Nat Immunol. 2017 Mar;18(3):354-363. doi: 10.1038/ni.3665. Epub 2017 Jan 23.

24.

Novel immunotherapies for the treatment of melanoma.

Gato-Cañas M, Arasanz H, Blanco-Luquin I, Glaría E, Arteta-Sanchez V, Kochan G, Escors D.

Immunotherapy. 2016 May;8(5):613-32. doi: 10.2217/imt-2015-0024. Review.

PMID:
27140413
25.

Gene promoter hypermethylation is found in sentinel lymph nodes of breast cancer patients, in samples identified as positive by one-step nucleic acid amplification of cytokeratin 19 mRNA.

Martín-Sánchez E, Pernaut-Leza E, Mendaza S, Cordoba A, Vicente-Garcia F, Monreal-Santesteban I, Vizcaino JP, De Cerio MJ, Perez-Janices N, Blanco-Luquin I, Escors D, Ulazia-Garmendia A, Guerrero-Setas D.

Virchows Arch. 2016 Jul;469(1):51-9. doi: 10.1007/s00428-016-1941-x. Epub 2016 Apr 21.

PMID:
27097811
26.

Signal transducer and activator of transcription 3 in myeloid-derived suppressor cells: an opportunity for cancer therapy.

Dufait I, Van Valckenborgh E, Menu E, Escors D, De Ridder M, Breckpot K.

Oncotarget. 2016 Jul 5;7(27):42698-42715. doi: 10.18632/oncotarget.8311. Review.

27.

Distinct Activation Mechanisms of NF-κB Regulator Inhibitor of NF-κB Kinase (IKK) by Isoforms of the Cell Death Regulator Cellular FLICE-like Inhibitory Protein (cFLIP).

Baratchian M, Davis CA, Shimizu A, Escors D, Bagnéris C, Barrett T, Collins MK.

J Biol Chem. 2016 Apr 1;291(14):7608-20. doi: 10.1074/jbc.M116.718122. Epub 2016 Feb 10.

28.

Lentiviral expression of GAD67 and CCK promoter-driven opsins to target interneurons in vitro and in vivo.

Mantoan Ritter L, Macdonald DC, Ritter G, Escors D, Chiara F, Cariboni A, Schorge S, Kullmann DM, Collins M.

J Gene Med. 2016 Jan-Mar;18(1-3):27-37. doi: 10.1002/jgm.2873.

PMID:
26824337
29.

[Dendritic cells in cancer immunotherapy].

Gato M, Liechtenstein T, Blanco-Luquín I, Zudaire MI, Kochan G, Escors D.

An Sist Sanit Navar. 2015 May-Aug;38(2):279-87. Spanish.

30.

Drafting the proteome landscape of myeloid-derived suppressor cells.

Gato M, Blanco-Luquin I, Zudaire M, de Morentin XM, Perez-Valderrama E, Zabaleta A, Kochan G, Escors D, Fernandez-Irigoyen J, Santamaría E.

Proteomics. 2016 Jan;16(2):367-78. doi: 10.1002/pmic.201500229. Epub 2015 Dec 14. Review.

PMID:
26403437
31.

The transduction pattern of IL-12-encoding lentiviral vectors shapes the immunological outcome.

Goyvaerts C, Broos K, Escors D, Heirman C, Raes G, De Baetselier P, Thielemans K, Breckpot K.

Eur J Immunol. 2015 Dec;45(12):3351-61. doi: 10.1002/eji.201545559. Epub 2015 Oct 27.

32.

A core of kinase-regulated interactomes defines the neoplastic MDSC lineage.

Gato-Cañas M, Martinez de Morentin X, Blanco-Luquin I, Fernandez-Irigoyen J, Zudaire I, Liechtenstein T, Arasanz H, Lozano T, Casares N, Chaikuad A, Knapp S, Guerrero-Setas D, Escors D, Kochan G, Santamaría E.

Oncotarget. 2015 Sep 29;6(29):27160-75. doi: 10.18632/oncotarget.4746.

33.

Differential involvement of RASSF2 hypermethylation in breast cancer subtypes and their prognosis.

Perez-Janices N, Blanco-Luquin I, Torrea N, Liechtenstein T, Escors D, Cordoba A, Vicente-Garcia F, Jauregui I, De La Cruz S, Illarramendi JJ, Coca V, Berdasco M, Kochan G, Ibañez B, Lera JM, Guerrero-Setas D.

Oncotarget. 2015 Sep 15;6(27):23944-58.

34.

Differential role of gene hypermethylation in adenocarcinomas, squamous cell carcinomas and cervical intraepithelial lesions of the uterine cervix.

Blanco-Luquin I, Guarch R, Ojer A, Pérez-Janices N, Martín-Sánchez E, Maria-Ruiz S, Monreal-Santesteban I, Blanco-Fernandez L, Pernaut-Leza E, Escors D, Guerrero-Setas D.

Pathol Int. 2015 Sep;65(9):476-85. doi: 10.1111/pin.12332. Epub 2015 Jul 27.

PMID:
26222671
35.

Ex vivo generation of myeloid-derived suppressor cells that model the tumor immunosuppressive environment in colorectal cancer.

Dufait I, Schwarze JK, Liechtenstein T, Leonard W, Jiang H, Escors D, De Ridder M, Breckpot K.

Oncotarget. 2015 May 20;6(14):12369-82.

36.

Construction of stable packaging cell lines for clinical lentiviral vector production.

Sanber KS, Knight SB, Stephen SL, Bailey R, Escors D, Minshull J, Santilli G, Thrasher AJ, Collins MK, Takeuchi Y.

Sci Rep. 2015 Mar 12;5:9021. doi: 10.1038/srep09021.

37.

EPB41L3, TSP-1 and RASSF2 as new clinically relevant prognostic biomarkers in diffuse gliomas.

Perez-Janices N, Blanco-Luquin I, Tuñón MT, Barba-Ramos E, Ibáñez B, Zazpe-Cenoz I, Martinez-Aguillo M, Hernandez B, Martínez-Lopez E, Fernández AF, Mercado MR, Cabada T, Escors D, Megias D, Guerrero-Setas D.

Oncotarget. 2015 Jan 1;6(1):368-80.

38.

Intratumoral administration of mRNA encoding a fusokine consisting of IFN-β and the ectodomain of the TGF-β receptor II potentiates antitumor immunity.

Van der Jeught K, Joe PT, Bialkowski L, Heirman C, Daszkiewicz L, Liechtenstein T, Escors D, Thielemans K, Breckpot K.

Oncotarget. 2014 Oct 30;5(20):10100-13.

39.

A highly efficient tumor-infiltrating MDSC differentiation system for discovery of anti-neoplastic targets, which circumvents the need for tumor establishment in mice.

Liechtenstein T, Perez-Janices N, Gato M, Caliendo F, Kochan G, Blanco-Luquin I, Van der Jeught K, Arce F, Guerrero-Setas D, Fernandez-Irigoyen J, Santamaria E, Breckpot K, Escors D.

Oncotarget. 2014 Sep 15;5(17):7843-57.

40.

The kinase p38 activated by the metabolic regulator AMPK and scaffold TAB1 drives the senescence of human T cells.

Lanna A, Henson SM, Escors D, Akbar AN.

Nat Immunol. 2014 Oct;15(10):965-72. doi: 10.1038/ni.2981. Epub 2014 Aug 24.

41.

Pseudaminic acid on Campylobacter jejuni flagella modulates dendritic cell IL-10 expression via Siglec-10 receptor: a novel flagellin-host interaction.

Stephenson HN, Mills DC, Jones H, Milioris E, Copland A, Dorrell N, Wren BW, Crocker PR, Escors D, Bajaj-Elliott M.

J Infect Dis. 2014 Nov 1;210(9):1487-98. doi: 10.1093/infdis/jiu287. Epub 2014 May 13.

42.
43.

Role of non-classical MHC class I molecules in cancer immunosuppression.

Kochan G, Escors D, Breckpot K, Guerrero-Setas D.

Oncoimmunology. 2013 Nov 1;2(11):e26491. Epub 2013 Oct 21. Review.

44.

Interference with PD-L1/PD-1 co-stimulation during antigen presentation enhances the multifunctionality of antigen-specific T cells.

Pen JJ, Keersmaecker BD, Heirman C, Corthals J, Liechtenstein T, Escors D, Thielemans K, Breckpot K.

Gene Ther. 2014 Mar;21(3):262-71. doi: 10.1038/gt.2013.80. Epub 2014 Jan 9.

PMID:
24401835
45.

Anti-melanoma vaccines engineered to simultaneously modulate cytokine priming and silence PD-L1 characterized using ex vivo myeloid-derived suppressor cells as a readout of therapeutic efficacy.

Liechtenstein T, Perez-Janices N, Blanco-Luquin I, Goyvaerts C, Schwarze J, Dufait I, Lanna A, Ridder M, Guerrero-Setas D, Breckpot K, Escors D.

Oncoimmunology. 2014 Jul 3;3(7):e945378. eCollection 2014.

46.

Assessing T-cell responses in anticancer immunotherapy: Dendritic cells or myeloid-derived suppressor cells?

Escors D, Liechtenstein T, Perez-Janices N, Schwarze J, Dufait I, Goyvaerts C, Lanna A, Arce F, Blanco-Luquin I, Kochan G, Guerrero-Setas D, Breckpot K.

Oncoimmunology. 2013 Oct 1;2(10):e26148. Epub 2013 Sep 12. Review.

47.

Lentiviral vectors for cancer immunotherapy and clinical applications.

Liechtenstein T, Perez-Janices N, Escors D.

Cancers (Basel). 2013 Sep;5(3):815-37. doi: 10.3390/cancers5030815.

48.

Impact of T cell selection methods in the success of clinical adoptive immunotherapy.

Ramírez N, Beloki L, Ciaúrriz M, Rodríguez-Calvillo M, Escors D, Mansilla C, Bandrés E, Olavarría E.

Cell Mol Life Sci. 2014 Apr;71(7):1211-24.

PMID:
24077876
49.

Novel function for the p38-MK2 signaling pathway in circulating CD1c+ (BDCA-1+) myeloid dendritic cells from healthy donors and advanced cancer patients; inhibition of p38 enhances IL-12 whilst suppressing IL-10.

Franks HA, Wang Q, Lax SJ, Collins MK, Escors D, Patel PM, Jackson AM.

Int J Cancer. 2014 Feb 1;134(3):575-86. doi: 10.1002/ijc.28398. Epub 2013 Sep 13.

50.

Modulation of regulatory T cell function by monocyte-derived dendritic cells matured through electroporation with mRNA encoding CD40 ligand, constitutively active TLR4, and CD70.

Pen JJ, De Keersmaecker B, Maenhout SK, Van Nuffel AM, Heirman C, Corthals J, Escors D, Bonehill A, Thielemans K, Breckpot K, Aerts JL.

J Immunol. 2013 Aug 15;191(4):1976-83. doi: 10.4049/jimmunol.1201008. Epub 2013 Jul 10.

Supplemental Content

Loading ...
Support Center